Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly

Clinics in Geriatric Medicine

Volumn 23, Issue 1, 2007, Pages 61-81

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FUROSEMIDE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOOP DIURETIC AGENT; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; RAMIPRIL; SPIRONOLACTONE; THIAMINE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VALSARTAN; WARFARIN;

ANGIONEUROTIC EDEMA; ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; BACTERIAL ENDOCARDITIS; BERIBERI; BETA ADRENERGIC RECEPTOR BLOCKING; BRADYCARDIA; CLINICAL TRIAL; COUGHING; DEHYDRATION; DIABETES MELLITUS; DIGITALIS INTOXICATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ERUPTION; FATIGUE; FLUID RETENTION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VALVE REPLACEMENT; HEART VALVE STENOSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; INDUCED HYPOTENSION; KIDNEY FAILURE; LUNG EDEMA; LUNG EMBOLISM; META ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TASTE DISORDER; UREMIA;

AGED; CARDIOTONIC AGENTS; CLINICAL TRIALS; DIURETICS; HEART FAILURE, CONGESTIVE; HUMANS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33751275224     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2006.08.004     Document Type: Review

References (101)

1. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article. Circulation 112 (2005) 1825-1852
2. Aronow W.S. What is the appropriate treatment of hypertension in elders?. J Gerontol: Med Sci 57A (2002) M483-M486
3. Aronow W.S. Treatment of older persons with hypercholesterolemia with and without cardiovascular disease. J Gerontol Med Sci 56A (2001) M138-M145
4. Aronow W.S., and Ahn C. Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dL treated with statins versus no lipid-lowering drug. Am J Cardiol 90 (2002) 147-149
5. Aronow W.S., and Ahn C. Elderly diabetics with peripheral arterial disease and no coronary artery disease have a higher incidence of new coronary events than elderly nondiabetics with peripheral arterial disease and prior myocardial infarction treated with statins and with no lipid-lowering drug. J Gerontol: Med Sci 58A (2003) M573-M575
6. Sanal S., and Aronow W.S. Effect of an educational program on the prevalence of use of antiplatelet drugs, beta blockers, angiotensin-converting enzyme inhibitors, lipid-lowering drugs, and calcium channel blockers prescribed during hospitalization and at hospital discharge in patients with coronary artery disease. J Gerontol: Med Sci 58A (2003) M1046-M1048
7. Ghosh S., and Aronow W.S. Utilization of lipid-lowering drugs in elderly persons with increased serum low-density lipoprotein cholesterol associated with coronary artery disease, symptomatic peripheral arterial disease, prior stroke, or diabetes mellitus before and after an educational program on dyslipidemia treatment. J Gerontol: Med Sci 58A (2003) M432-M435
8. Aronow W.S. Exercise therapy for older persons with cardiovascular disease. Am J Geriatr Cardiol 10 (2001) 245-252
9. Rich M.W., Beckham V., Wittenberg C., et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333 (1995) 1190-1195
10. Neuberg G.W., Miller A.B., O'Connor C.M., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002) 31-38
11. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987) 1429-1435
12. Cohn J., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
14. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
15. Garg R., and Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 273 (1995) 1450-1456
16. Pfeffer M.A., Braunwald E., Moye L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327 (1992) 669-677
17. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
18. Kober L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
19. Aronow W.S., Ahn C., and Kronzon I. Effect of beta blockers alone, of angiotensin-converting enzyme inhibitors alone, and of beta blockers plus angiotensin-converting enzyme inhibitors on new coronary events and on congestive heart failure in older persons with healed myocardial infarcts and asymptomatic left ventricular systolic dysfunction. Am J Cardiol 88 (2001) 1298-1300
20. Packer M., Poole-Wilson P.A., Armstrong P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 (1999) 2312-2318
21. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351 (2004) 2049-2057
22. Exner D.V., Dries D.L., Domanski M.J., et al. Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 (2001) 1351-1357
23. Dries D.L., Strong M.H., Cooper R.S., et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 40 (2002) 311-317
24. Vanhoutte P.M., Auch-schwelk W., Biondi M.L., et al. Why are converting enzyme inhibitors vasodilators?. Br J Clin Pharmacol 28 (1989) 95S-104S
25. Weksler B.B., Pett S.B., Alonso D., et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 308 (1983) 800-805
26. Hall D., Zeitler H., and Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 20 (1994) 1549-1555
27. Boger R.H., Bodeboger S.M., Kramme P., et al. Effect of captopril on prostacyclin and nitric oxide formation in healthy human subjects: interaction with low dose acetylsalicylic acid. Br J Clin Pharmacol 42 (1996) 721-727
28. Evans M.A., Burnett Jr. J.C., and Redfield M.M. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol 25 (1995) 1445-1450
29. Katz S.D., Radin M., Graves T., et al. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril. J Am Coll Cardiol 34 (1999) 170-176
30. Nguyen K.N., Aursnes I., and Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 79 (1997) 115-119
31. Al-Khadra A.S., Salem D.N., Rand W.M., et al. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 31 (1998) 419-425
32. Leor J., Reicher-Reiss H., Goldbourt U., et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 33 (1999) 1920-1925
33. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355 (2000) 1575-1581
34. Lapane K.L., Hume A.L., Barbour M.M., et al. Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure?. J Am Geriatr Soc 50 (2002) 1198-1204
35. Dzau V.J. Tissue renin-angiotensin system in myocardial hypertrophy and failure. Arch Intern Med 153 (1993) 937-942
36. Jilma B., Krejcy K., Dirnberger E., et al. Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci 60 (1997) 1859-1866
37. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
38. Lindholm L.H., Ibsen H., Dahlof B., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
39. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
40. Cohn J.N., and Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
41. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
42. Granger C.B., McMurray J.J.V., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
43. McMurray J.J.V., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
44. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362 (2003) 777-781
45. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247 (1982) 1707-1714
46. Pedersen T.R. Six-year follow-up of the Norwegian Multicentre Study on Timolol after acute myocardial infarction. N Engl J Med 313 (1985) 1055-1058
47. Chadda K., Goldstein S., Byington R., et al. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73 (1986) 503-510
48. Kennedy H.L., Brooks M.M., Barker A.H., et al. Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. Am J Cardiol 74 (1994) 674-680
49. Aronow W.S., Ahn C., Mercando A.D., et al. Effect of propranolol versus no antiarrhythmic drug on sudden cardiac death, total cardiac death, and total death in patients ≥62 years of age with heart disease, complex ventricular arrhythmias, and left ventricular ejection fraction ≥40%. Am J Cardiol 74 (1994) 267-270
50. Aronow W.S., and Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and diabetes mellitus. Am J Cardiol 87 (2001) 780-781
51. Aronow W.S., and Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 87 (2001) 1284-1286
52. Furberg C.D., Hawkins C.M., and Lichstein E. Effect of propranolol in postinfarction patients with mechanical or electrical complications. Circulation 69 (1984) 761-765
53. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
54. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999) 9-13
55. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
56. Packer M., Coats A.J.S., Fowler M.B., et al. Effect of carvedilol on survival in chronic heart failure. N Engl J Med 344 (2001) 651-658
57. Flather M.D., Shibata M.C., Coats A.J.S., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (2005) 215-225
58. Mann D.L., Deswal A., Bozkurt B., et al. New therapeutics for chronic heart failure. Annu Rev Med 53 (2002) 59-74
59. Ohtsuka T., Hamada M., Hiasa G., et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 37 (2001) 412-417
60. Wiklund O., Hulthe J., Wikstrand J., et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 33 (2002) 572-577
61. Moye L., and Pfeffer M. Additional beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 29 (1997) 229-236
62. Exner D.V., Dries D.L., Waclawiw M.A., et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 33 (1999) 916-923
63. Task Force for the Diagnosis and Treatment of Chronic Heart Failure. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22 (2001) 1527-1560
64. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
65. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
66. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 314 (1986) 1547-1552
67. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (1997) 525-533
68. Rich M.W., McSherry F., Williford W.O., et al. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG Study. J Am Coll Cardiol 38 (2001) 806-813
69. Rathore S.S., Wang Y., and Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 347 (2002) 1403-1411
70. Rathore S.S., Curtis J.P., Wang Y., et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003) 871-878
71. Ahmed A, Aban IB, Weaver MT, et al. Serum digoxin concentration and outcomes in women with heart failure: a bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Failure, accepted for publication.
72. Aronow W.S. Digoxin or angiotensin converting enzyme inhibitors for congestive heart failure in geriatric patients. Which is the preferred treatment?. Drugs Aging 1 (1991) 98-103
73. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 106 (2002) 920-926
74. Abraham W.T., Ascheim D., Demarco T., et al. Effects of enrasentan, a nonselective endothelin receptor antagonist in class II to III heart failure: results of the Enrasentan Cooperative Randomized (ENCOR) Evaluation. J Am Coll Cardiol 38 (2001) 612
75. McMurray J., and Pfeffer M.A. New therapeutic options in congestive heart failure. Part II. Circulation 105 (2002) 2223-2228
76. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 291 (2004) 1963-1971
77. Francis G.S., and Tang W.H.W. Vasopressin receptor antagonists. Will the "vaptans" fulfill their promise?. JAMA 291 (2004) 2017-2018
78. Elkayam U., Amin J., Mehra A., et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 82 (1990) 1954-1961
79. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319 (1988) 385-392
80. Goldstein R.E., Boccuzzi S.J., Cruess D., et al. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. Circulation 83 (1991) 52-60
81. Packer M., O'Connor C.M., Ghali J.K., et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 335 (1996) 1107-1114
82. Cohn J.N., Ziesche S., Smith R., et al. Effect of the calcium antagonist felodipine as suplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. V-HeFT III. Circulation 96 (1997) 856-863
83. Aronow W.S. CRT plus ICD in congestive heart failure. Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction. Geriatrics 60 2 (2005) 24-28
84. Young J.B., Abraham W.T., Smith A.L., et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure. The MIRACLE ICD trial. JAMA 289 (2003) 2685-2694
85. Bristow M.R., Saxon L.A., Boehmer J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350 (2004) 2140-2150
86. Cleland J.G.F., Daubert J.-C., Erdmann E., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
87. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
88. Packer M., Carver J.R., Rodeheffer R.J., et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325 (1991) 1468-1475
89. Packer M., Rouleau J., Swedberg K., et al. Effect of flosequinan on survival in chronic heart failure: preliminary results of the PROFILE study. [abstract]. Circulation 88 suppl I (1993) I-301
90. Uretsky B.F., Jessup F., Konstan M.A., et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 82 (1990) 774-780
91. Cohn J.N., Goldstein S.O., Greenberg B.H., et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 339 (1998) 1810-1816
92. Pimobendan in Congestive Heart Failure (PICO) Investigators. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) Trial. Heart 76 (1996) 223-231
93. Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 336 (1990) 1-6
94. Hampton J.R., Van Veldhusisen D.J., Kleber F.X., et al. Randomized study of effect of ibopamine on survival in patients with advanced heart failure. Lancet 349 (1997) 971-977
95. O'Connor C.M., Gattis W.A., Uretsky B.F., et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138 (2000) 78-86
96. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized controlled trial. JAMA 287 (2002) 1531-1540
97. Teerlink J.R., and Massie B.M. Nesiritide and worsening of renal function. The emperor's new clothes?. Circulation 111 (2005) 1459-1461
98. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
99. Sackner-Bernstein J.D., Kowalski M., Fox M., et al. Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA 293 (2005) 1900-1905
100. Athanasuleas C.L., Stanley Jr. A.W., Buckberg G.D., et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. J Am Coll Cardiol 37 (2001) 1210-1213
101. Rose E.A., Gelijns A.C., Moskowitz A.J., et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345 (2001) 1435-1443